As an array of developers push their Friedreich’s ataxia (FA) drugs along, PTC Therapeutics Inc.’s recent update on its program piqued thirst for the 15-lipoxygenase inhibitor vatiquinone. Warren, N.J ...
The following is a summary of “Prevalence and outcomes of cancer and treatment-associated toxicities for patients with Ataxia Telangiectasia,” published in the November 2024 issue of Allergy and ...
More than 95% of individuals with Friedreich’s ataxia have a GAA repeat expansion as the disease-causing mutation, leading to systemic loss of frataxin protein. In preclinical studies ...